Savient Pharmaceuticals Overview

  • Year Founded
  • 1980

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 122

Employees

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 4

  • Investments
  • 2

Savient Pharmaceuticals General Information

Description

Operator of a specialty biopharmaceutical company. The company and its subsidiaries are focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader specialty markets.

Contact Information

Formerly Known As
Bio Technology General, Bio Technology General Corp
Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Corporate Office
  • 400 Crossing Boulevard
  • Bridgewater, NJ 08807
  • United States
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Biotechnology
Corporate Office
  • 400 Crossing Boulevard
  • Bridgewater, NJ 08807
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Savient Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Savient Pharmaceuticals‘s full profile, request access.

Request a free trial

Savient Pharmaceuticals Patents

Savient Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2010151823-A1 Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy Inactive 25-Jun-2009
AU-2010265879-A1 Methods for assessing tophus response during urate lowering therapy in treatment tophaceous gout Inactive 25-Jun-2009
CA-2764761-A1 Methods for assessing tophus response during urate lowering therapy in treatment tophaceous gout Inactive 25-Jun-2009
EP-2445514-A1 Methods for assessing tophus response during urate lowering therapy in treatment tophaceous gout Inactive 25-Jun-2009
US-20120323107-A1 Methods for assessing tophus response during urate lowering therapy in treatment tophaceous gout Inactive 25-Jun-2009 G01N33/6893
To view Savient Pharmaceuticals’s complete patent history, request access »

Savient Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Savient Pharmaceuticals Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Savient Pharmaceuticals‘s full profile, request access.

Request a free trial

Savient Pharmaceuticals Investments & Acquisitions (2)

Savient Pharmaceuticals’s most recent deal was a Merger/Acquisition with Myelos Neurosciences for . The deal was made on 19-Mar-2001.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Myelos Neurosciences 19-Mar-2001 Merger/Acquisition Therapeutic Devices
Omrix Biopharmaceuticals 04-Sep-1999 Early Stage VC Biotechnology
To view Savient Pharmaceuticals’s complete investments and acquisitions history, request access »

Savient Pharmaceuticals Exits (1)

Savient Pharmaceuticals’s most recent exit was on 04-Sep-1999 from Omrix Biopharmaceuticals. The exit was categorized as with 3 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Omrix Biopharmaceuticals 04-Sep-1999 Completed
  • 3 buyers
To view Savient Pharmaceuticals’s complete exits history, request access »

Savient Pharmaceuticals FAQs

  • When was Savient Pharmaceuticals founded?

    Savient Pharmaceuticals was founded in 1980.

  • Where is Savient Pharmaceuticals headquartered?

    Savient Pharmaceuticals is headquartered in Bridgewater, NJ.

  • What is the size of Savient Pharmaceuticals?

    Savient Pharmaceuticals has 122 total employees.

  • What industry is Savient Pharmaceuticals in?

    Savient Pharmaceuticals’s primary industry is Buildings and Property.

  • Is Savient Pharmaceuticals a private or public company?

    Savient Pharmaceuticals is a Private company.

  • What is the current valuation of Savient Pharmaceuticals?

    The current valuation of Savient Pharmaceuticals is .

  • What is Savient Pharmaceuticals’s current revenue?

    The current revenue for Savient Pharmaceuticals is .

  • Who are Savient Pharmaceuticals’s investors?

    Franklin Templeton, Palo Alto Investors, and Wellington Management have invested in Savient Pharmaceuticals.

  • When was Savient Pharmaceuticals acquired?

    Savient Pharmaceuticals was acquired on 13-Jan-2014.

  • Who acquired Savient Pharmaceuticals?

    Savient Pharmaceuticals was acquired by Crealta Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process